MX2020012770A - Seleccion y uso de bacterias que favorecen la produccion de melatonina para reducir el colico infantil. - Google Patents
Seleccion y uso de bacterias que favorecen la produccion de melatonina para reducir el colico infantil.Info
- Publication number
- MX2020012770A MX2020012770A MX2020012770A MX2020012770A MX2020012770A MX 2020012770 A MX2020012770 A MX 2020012770A MX 2020012770 A MX2020012770 A MX 2020012770A MX 2020012770 A MX2020012770 A MX 2020012770A MX 2020012770 A MX2020012770 A MX 2020012770A
- Authority
- MX
- Mexico
- Prior art keywords
- melatonin
- selection
- reduce
- infantile colic
- strains
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003987 melatonin Drugs 0.000 title abstract 4
- 208000002881 Colic Diseases 0.000 title abstract 2
- 206010021746 Infantile colic Diseases 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03031—Nucleotidase (3.1.3.31)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a cepas bacterianas de ácido láctico que son capaces de producir o inducir la producción de melatonina, para su uso en la producción de melatonina en un sujeto. Las cepas preferidas para tales usos son capaces de producir o inducir la producción de adenosina. Los usos terapéuticos de tales cepas incluyen el tratamiento o la prevención de enfermedades asociadas con la deficiencia de melatonina, por ejemplo, el cólico infantil. También se proporcionan nuevas cepas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1812079.0A GB201812079D0 (en) | 2018-07-24 | 2018-07-24 | Selection method |
| GBGB1905470.9A GB201905470D0 (en) | 2019-04-17 | 2019-04-17 | Selection method |
| PCT/EP2019/069984 WO2020020982A1 (en) | 2018-07-24 | 2019-07-24 | Selection and use of melatonin supporting bacteria to reduce infantile colic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012770A true MX2020012770A (es) | 2021-02-15 |
Family
ID=67390083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012770A MX2020012770A (es) | 2018-07-24 | 2019-07-24 | Seleccion y uso de bacterias que favorecen la produccion de melatonina para reducir el colico infantil. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11911424B2 (es) |
| EP (2) | EP3701051B1 (es) |
| JP (1) | JP7488199B2 (es) |
| KR (1) | KR20210035077A (es) |
| CN (2) | CN117487686A (es) |
| AU (1) | AU2019309426A1 (es) |
| BR (1) | BR112020023868A2 (es) |
| CA (1) | CA3099255A1 (es) |
| CL (1) | CL2020003070A1 (es) |
| CO (1) | CO2020014673A2 (es) |
| DK (1) | DK3701051T3 (es) |
| ES (1) | ES2928223T3 (es) |
| GE (1) | GEP20237507B (es) |
| HR (1) | HRP20221209T1 (es) |
| HU (1) | HUE059963T2 (es) |
| IL (1) | IL305597B1 (es) |
| LT (1) | LT3701051T (es) |
| MX (1) | MX2020012770A (es) |
| PH (1) | PH12020551922A1 (es) |
| PL (1) | PL3701051T3 (es) |
| PT (1) | PT3701051T (es) |
| RS (1) | RS63624B1 (es) |
| SG (1) | SG11202010900PA (es) |
| WO (1) | WO2020020982A1 (es) |
| ZA (1) | ZA202006891B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3827102A1 (en) * | 2018-07-24 | 2021-06-02 | Biogaia AB | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
| CN115040551B (zh) * | 2022-06-08 | 2023-07-25 | 华南农业大学 | 一株调控宿主褪黑素水平的罗伊氏乳酸杆菌ln0214的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
| US20080058405A1 (en) | 2006-07-31 | 2008-03-06 | Oregon Health & Science University | Replicating melatonin signaling in a fetus, newborn or suckling infant |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| KR100913406B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물 |
| BRPI0921617A2 (pt) | 2008-11-03 | 2015-08-18 | Nestec Sa | Composicao nutricional compreendendo probioticos e padroes do sono aperfeicoados |
| EP2452575A1 (en) | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of age-tailored nutritional formula with probiotics |
| EP2609813A1 (en) | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
| ITMI20120471A1 (it) | 2012-03-26 | 2013-09-27 | Giovanni Mogna | Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita |
| GB201206599D0 (en) * | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| EP2674162A1 (en) | 2012-05-29 | 2013-12-18 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
| UA118339C2 (uk) | 2012-09-03 | 2019-01-10 | Біогайа Аб | Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти) |
| WO2015112083A1 (en) | 2014-01-23 | 2015-07-30 | Biogaia Ab | Selection of agents modulating gastrointestinal pain |
| EP3145520A2 (en) | 2014-05-20 | 2017-03-29 | Biogaia AB | Neonatal microbiome supplementation |
| SG11201610413RA (en) | 2014-06-30 | 2017-02-27 | Meiji Co Ltd | Lactic acid bacteria suppressing purine absorption and use thereof |
| CA2971520C (en) * | 2014-12-23 | 2024-04-09 | Ilya Pharma Ab | Methods for wound healing |
| RU2747390C2 (ru) | 2015-03-26 | 2021-05-04 | Биогайа Аб | Продуцирующие гистамин бактериальные штаммы и их применение при злокачественных опухолях |
| CN110087656A (zh) | 2016-05-27 | 2019-08-02 | 拜奥加亚公司 | 肌苷在治疗T-reg缺乏中的应用 |
| WO2017223364A1 (en) * | 2016-06-23 | 2017-12-28 | Erdman Susan E | Canine microbe preparations for increasing oxytocin |
| CN108029923A (zh) | 2017-12-13 | 2018-05-15 | 杭州滨研生物科技有限公司 | 一种具有抗过敏效果的益生菌固体饮料生产配方 |
| EP3827102A1 (en) | 2018-07-24 | 2021-06-02 | Biogaia AB | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
-
2019
- 2019-07-24 PL PL19742381.7T patent/PL3701051T3/pl unknown
- 2019-07-24 DK DK19742381.7T patent/DK3701051T3/da active
- 2019-07-24 HU HUE19742381A patent/HUE059963T2/hu unknown
- 2019-07-24 IL IL305597A patent/IL305597B1/en unknown
- 2019-07-24 BR BR112020023868-6A patent/BR112020023868A2/pt unknown
- 2019-07-24 CA CA3099255A patent/CA3099255A1/en active Pending
- 2019-07-24 KR KR1020207033397A patent/KR20210035077A/ko unknown
- 2019-07-24 RS RS20220933A patent/RS63624B1/sr unknown
- 2019-07-24 HR HRP20221209TT patent/HRP20221209T1/hr unknown
- 2019-07-24 CN CN202311089611.3A patent/CN117487686A/zh active Pending
- 2019-07-24 WO PCT/EP2019/069984 patent/WO2020020982A1/en unknown
- 2019-07-24 US US16/961,598 patent/US11911424B2/en active Active
- 2019-07-24 ES ES19742381T patent/ES2928223T3/es active Active
- 2019-07-24 EP EP19742381.7A patent/EP3701051B1/en active Active
- 2019-07-24 EP EP22165915.4A patent/EP4086359A1/en active Pending
- 2019-07-24 CN CN201980036257.3A patent/CN112236513B/zh active Active
- 2019-07-24 LT LTEPPCT/EP2019/069984T patent/LT3701051T/lt unknown
- 2019-07-24 GE GEAP201915500A patent/GEP20237507B/en unknown
- 2019-07-24 PT PT197423817T patent/PT3701051T/pt unknown
- 2019-07-24 AU AU2019309426A patent/AU2019309426A1/en active Pending
- 2019-07-24 JP JP2020570056A patent/JP7488199B2/ja active Active
- 2019-07-24 SG SG11202010900PA patent/SG11202010900PA/en unknown
- 2019-07-24 MX MX2020012770A patent/MX2020012770A/es unknown
-
2020
- 2020-11-04 ZA ZA2020/06891A patent/ZA202006891B/en unknown
- 2020-11-11 PH PH12020551922A patent/PH12020551922A1/en unknown
- 2020-11-26 CO CONC2020/0014673A patent/CO2020014673A2/es unknown
- 2020-11-26 CL CL2020003070A patent/CL2020003070A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11911424B2 (en) | 2024-02-27 |
| BR112020023868A2 (pt) | 2021-04-06 |
| WO2020020982A1 (en) | 2020-01-30 |
| ZA202006891B (en) | 2023-03-29 |
| DK3701051T3 (da) | 2022-10-03 |
| CO2020014673A2 (es) | 2020-12-21 |
| JP7488199B2 (ja) | 2024-05-21 |
| PH12020551922A1 (en) | 2021-06-14 |
| ES2928223T3 (es) | 2022-11-16 |
| EP3701051A1 (en) | 2020-09-02 |
| PL3701051T3 (pl) | 2022-10-31 |
| LT3701051T (lt) | 2022-12-12 |
| EP3701051B1 (en) | 2022-07-13 |
| CA3099255A1 (en) | 2020-01-30 |
| CL2020003070A1 (es) | 2021-04-05 |
| EP4086359A1 (en) | 2022-11-09 |
| RS63624B1 (sr) | 2022-10-31 |
| KR20210035077A (ko) | 2021-03-31 |
| IL305597B1 (en) | 2024-04-01 |
| CN117487686A (zh) | 2024-02-02 |
| HRP20221209T1 (hr) | 2022-12-09 |
| IL305597A (en) | 2023-11-01 |
| PT3701051T (pt) | 2022-10-17 |
| US20220347237A1 (en) | 2022-11-03 |
| CN112236513B (zh) | 2023-09-19 |
| HUE059963T2 (hu) | 2023-01-28 |
| GEP20237507B (en) | 2023-05-25 |
| CN112236513A (zh) | 2021-01-15 |
| SG11202010900PA (en) | 2020-12-30 |
| JP2021531739A (ja) | 2021-11-25 |
| AU2019309426A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009539A (es) | Uso de comunidades microbianas para la salud humana y animal. | |
| MX2019014045A (es) | Composiciones y metodos. | |
| PH12019502828A1 (en) | Diazabicylic substituted imidazopyrimides and their use for the treatment of breathing disorders | |
| MX2019007613A (es) | Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos. | |
| TN2012000067A1 (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| MY162708A (en) | Use of selected lactic acid bacteria for reducing infantile colic | |
| PH12020551922A1 (en) | Selection and use of melatonin supporting bacteria to reduce infantile colic | |
| MX2017006383A (es) | Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes. | |
| MX2022007994A (es) | Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos. | |
| MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
| MX2021007508A (es) | Derivados de oxopiridina sustituidos. | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| UA118339C2 (uk) | Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти) | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| MX2018008643A (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano. | |
| MX2021012631A (es) | Microvesiculas terapeuticas de bacterias probioticas. | |
| WO2015170158A8 (en) | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation | |
| PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| NZ745187A (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2018230960A3 (ko) | 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 | |
| MX2021004860A (es) | Piridazinas novedosas. | |
| MX2022005064A (es) | Bacterias productoras de serotonina. |